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Objectives: Clostridium difficile infection (CDI) costs the US health care system over 
$3 billion annually. Current guidelines recommend metronidazole as first-line ther-
apy in most instances of CDI. However, vancomycin is recommended for recurrent 
CDI (RCDI). A growing body of evidence supports the use of fecal microbiota trans-
plantation (FMT) as a therapeutic option for RCDI. This study explores cost-effec-
tiveness of FMT and vancomycin versus metronidazole for initial CDI. MethOds: 
We constructed a decision-analytic computer simulation using inputs from the pub-
lished literature to compare a 10-14-day course of oral metronidazole or vancomycin 
to FMT for initial CDI. Parameters included cure rates (range) for metronidazole [80% 
(65-85%)], vancomycin [90% (88-92%)] and FMT [91% (83-100%)]. The direct costs 
(range) of metronidazole, vancomycin and FMT, adjusted to 2011 dollars, were $57 
($43-72), $1347 ($1195-1499) and $1086 ($815-1358), respectively. Our effectiveness 
measure was quality-adjusted life years (QALYs). Analysis was performed from the 
3rd-party payer perspective and one-way and probabilistic sensitivity analyses were 
conducted. Results: Base case analysis showed that FMT ($1585, 0.242 QALYs) was 
more costly and more effective than metronidazole ($1167, 0.238 QALYs), yielding 
an ICER of $101,647/QALY. FMT was dominant (less expensive and more effective) 
compared to vancomycin ($1890, 0.241 QALYs). One-way sensitivity analyses showed 
that metronidazole dominated both competing strategies if its probability of cure 
was > 90%; FMT dominated if it cost < $667. In a probabilistic sensitivity analysis at 
a willingness-to-pay threshold of $100,000/QALY, metronidazole was favored in 50% 
of model iterations; FMT was favored in 45%. cOnclusiOns: Our results suggest 
that metronidazole, as the first-line treatment for CDIs, may be less costly, but that 
FMT and vancomycin are more effective. However, FMT is less likely to be economi-
cally favorable, and vancomycin is unlikely to be favorable as first line therapy when 
compared to FMT, due to higher cost and less effectiveness.
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Objectives: Based on a recent indirect treatment comparison, golimumab showed 
comparability in efficacy and safety to infliximab and superiority to adalimumab in 
efficacy in terms of sustaining clinical outcomes. For this reason, a cost-effectiveness 
(CE) analysis comparing the three anti-TNF-α agents was conducted. MethOds: 
A Markov model was created to simulate patients over 10 years. The first admin-
istered intervention was any of the three biologics. Health states included clinical 
remission, clinical response, and relapse. Upon relapsing with the administered 
biologic, patients were assumed to transition into ‘relapse management’. Patients 
would then undergo colectomy and enter ‘post-colectomy remission’. Utilities were 
assigned separately for states before and after colectomy. Canadian cost estimates 
were used. Uncertainty around transition probabilities and cost estimates were 
incorporated. Sensitivity analyses included a societal perspective, varying discount 
rates, and time horizons, and ‘real world’ transition probabilities. Measures included 
total cost and utility over 10 years, mean incremental cost and utility per year, 
incremental CE ratios (ICERs), CE acceptability curves (CEACs) for golimumab and 
the CE frontier for all biologics. Results: In all analyses, golimumab yielded the 
lowest ICER. In the base case analysis, golimumab, infliximab, and adalimumab 
were associated with ICERs of approximately $40,000/QALY, $80,000/QALY, and 
$100,000/QALY, respectively. The CEAC for golimumab showed that a willingness-
to-pay threshold (WTPs) of $100,000/QALY was associated with a ~90% probability 
of being cost-effective. The cost-effectiveness frontier demonstrated that WTP 
thresholds greater than $25,000 showed that golimumab had the greatest prob-
ability of being cost-effective. Golimumab and infliximab displayed extended domi-
nance compared to adalimumab. Sensitivity analysis taking a societal perspective 
or using ‘real world’ transition probabilities reduced the ICERs by 20-40% for all 
biologics. cOnclusiOns: Overall golimumab provides a cost-effective treatment 
option for patients who have had an inadequate response to conventional therapy 
for moderately to severely active ulcerative colitis.
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Objectives: To evaluate the long-term impact of linaclotide on work productivity 
and activity impairment in adults with irritable bowel syndrome with constipa-
tion (IBS-C). MethOds: In a 26-week phase 3 trial, 804 adults meeting modified 
Rome II criteria for IBS-C were randomized to oral once-daily 290-mcg linaclotide or 
placebo. The self-administered 6-item Work Productivity and Activity Impairment 
Questionnaire for IBS-C (WPAI:IBS-C) evaluated IBS-C-related absenteeism (work 
hours missed), presenteeism (lost productivity at work), overall work productiv-
ity loss (absenteeism + presenteeism), and daily activity impairment (housework, 
shopping, childcare, exercising, etc) over the previous week at baseline and weeks 
4, 8, 12, 16, 20, and 26 during the treatment period. Overall work productivity losses 
were converted into monetary values using the human capital method by multiply-
ing total hours lost by average hourly employment cost of a US employee ($31.16 
in September 2013). Results: Of 804 patients, 780 (97.0%) completed a baseline 
and ≥ 1 postbaseline WPAI:IBS-C assessment. Of these, 586 patients (75.1%) were 
currently employed. Linaclotide treatment was associated with statistically signifi-
cant reductions in presenteeism, overall work productivity loss, and daily activity 
conducted to identify economic evaluations of IBD therapy reporting incremental 
cost-effectiveness or cost-utility ratios (ICERs or ICURs). The literature search was 
performed using electronic databases. Searches were limited to full economic evalu-
ations published in English or French between 2003 and 2013. Cross-reference of 
retrieved articles was also performed to identify additional publications. Results: 
A total of 15,242 potentially relevant studies were identified. After screening titles 
and abstracts, 43 full-text articles were assessed according to the eligibility criteria 
and 35 studies were included. Among those, 3 studies assessed the economic impact 
of IBD treatments with a companion diagnostic test. A high proportion of economic 
evaluations was performed from a third party payer perspective (91%) and had time 
horizons of 1 year or less (46%). European, American and Canadian economic evalua-
tions accounted for 66%, 17% and 11% of the studies respectively. Treatment options 
under evaluation included azathioprine, infliximab, adalimumab, immunosuppres-
sant and mesalamine. Most included studies were cost-utility analyses (94%), with 
ICURs ranging from dominant to CAD$11,934,934/QALY. More specifically, treatment 
under investigation was dominant in 26% of the analyses and was cost-effective 
according to a CAD$50,000/QALY and a CAD$100,000/QALY threshold in 31% and 
65% of the analyses respectively. cOnclusiOns: Several economic evaluations 
were conducted in the past years, with different parameters and results. As more 
treatment options become available, this review provides a comprehensive overview 
of evaluations previously performed and could be helpful in the realization of future 
economic evaluations.
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Objectives: Valganciclovir (VGV) is an antiviral agent used as prophylaxis of 
cytomegalovirus (CMV) infection following solid organ transplant. Limited studies 
regarding CMV prophylaxis with VGV in liver transplant recipients (LTR) have been 
performed. This study is a cost effectiveness analysis of VGV prevention strategies 
in LTR from a payer perspective. MethOds: We evaluated the cost of preventing 
hospitalization due to CMV in LTR at moderate to high risk of CMV. A decision 
tree model was constructed using TreeAge 2013. Data source for effectiveness was 
used from the results of our single-center retrospective analysis and cost data were 
from previously published data and the RedBook®. The model included costs of 
CMV prophylaxis, rates of CMV viremia, costs of outpatient treatment, and rates 
of inpatient admission due to CMV. We compared two protocols, one using lower 
doses and shorter duration of VGV prophylaxis (Group A) to a more recent protocol 
utilizing both higher doses and longer duration of VGV prophylaxis (Group B). Costs 
expressed in 2013 US dollars. Results: Costs associated with prophylaxis in group 
A were lower, despite a higher percentage of patients requiring treatment. Cost 
per-patient for prophylaxis in group A was $8,535.42 versus $14,926.73 in group 
B. In patients with CMV infection, 50% required hospitalization regardless of VGV 
prophylaxis group. Thus, 10% of patients in group A were hospitalized for treatment 
of CMV infection and only 4% of patients in group B required hospitalization. An 
ICER demonstrated that the prevention of one inpatient hospitalization due to CMV 
would cost $106,521.83. A one-way sensitivity analysis varying cost of VGV based 
on previously published costs demonstrated that the ICER for group B varies from 
$70,316 to $131,902. cOnclusiOns: While the increased dose and duration of VGV 
is effective at preventing CMV infection and hospitalization, it is associated with 
a large incremental cost.
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Objectives: Cigarette smoking increases the risk of postoperative complications. 
Preoperative smoking cessation programs may reduce surgical and post-operative 
complications, as well as the costs associated with treating them. We aimed to 
create an economic evaluation framework to estimate the potential value of pre-
operative smoking cessation programs for patients undergoing elective colorec-
tal surgery. MethOds: A decision-analytic model was developed from the payer 
perspective to integrate the costs and incidence of post-operative complications 
for a patient undergoing elective colorectal surgery after a smoking cessation 
program versus usual care. Incidence of post-operative complications in the 
first 30 days for smokers and recent quitters were derived from a cohort of 1,543 
patients undergoing elective colorectal resections in Washington State’s Surgical 
Care and Outcomes Assessment Program (2011-2013). Costs, smoking cessation 
program efficacy and alternative probabilities were obtained from the literature. 
Sensitivity analyses were performed to account for uncertainty in these esti-
mates. Results: For a cohort of 5,000 patients undergoing a preoperative smoking 
cessation program, the base case estimates imply the prevention of 9 respiratory 
complications, 16 infectious complications, and 2 thromboembolic complications, 
but there would be 4 more cardiovascular complications. The total direct medical 
costs of complications for patients who underwent a preoperative smoking ces-
sation program were on average $138 lower per patient than those in the usual 
care group during the first 30 days after surgery. The model was most sensitive 
to smoking cessation program effectiveness, but remained dominant across all 
sensitivity analyses. cOnclusiOns: A preoperative smoking cessation program 
is predicted to be cost-saving in the short term given the base case smoking ces-
sation efficacy of 22% if the cost of the intervention per patient is below $140. This 
framework allows payers to determine the value of smoking cessation programs 
of variable cost and effectiveness.
